13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001496201
Total reported value
$766.5M
$766.5M
104 檔
11.8%
The Q2 2025 SEC filing reveals that Sphera Funds Management LTD. held a total portfolio value of $766.5M, covering 104 public equity positions.
In Q2 2025, Sphera Funds Management LTD. adopted a defensive or profit-taking posture, trimming 53 positions and completely liquidating 27 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 6.38% | +1.19% | +3.10% | |
| 2 | NVMI | Nova Ltd. | Stock-Other | 4.90% | -1.90% | -16.39% | |
| 3 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 3.89% | -0.96% | — | |
| 4 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 3.45% | +0.20% | -5.55% | |
| 5 | TSEM | Tower Semiconductor Ltd. | Stock-Tech | 2.69% | -0.38% | +330.10% | |
| 6 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.53% | +0.43% | +125.38% | |
| 7 | SNY | Sanofi-adr | Stock-Healthcare | 2.49% | -0.56% | -27.91% | |
| 8 | BIIB | Biogen Inc | Stock-Healthcare | 2.44% | +2.85% | +263.88% | |
| 9 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.39% | -0.13% | -11.56% | |
| 10 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 2.21% | — | -22.85% | |
| 11 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.11% | -0.06% | -1.28% | |
| 12 | PRAX | Praxis Precision Medicines I | Stock-Other | 2.07% | +0.55% | NEW | |
| 13 | NVDA | Nvidia CORP | Stock-Tech | 2.02% | — | +84.14% | |
| 14 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.00% | -0.06% | -17.39% | |
| 15 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 1.71% | +0.05% | -10.50% | |
| 16 | AMZN | Amazon.com Inc | Stock-Consumer Disc | 1.67% | -1.06% | EXIT | |
| 17 | CDTX | Cidara Therapeutics Inc | Stock-Other | 1.58% | — | +705.70% | |
| 18 | ORA | Ormat Technologies Inc | Stock-Utilities | 1.53% | -0.81% | -7.14% | |
| 19 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.53% | -0.59% | +3.32% | |
| 20 | FBRX | Forte Biosciences Inc | Stock-Other | 1.50% | -0.07% | — | |
| 21 | META | Meta Platforms Inc-class A | Stock-Comm Services | 1.48% | — | -14.41% | |
| 22 | JNJ | Johnson & Johnson | Stock-Healthcare | 1.46% | -0.16% | -22.71% | |
| 23 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.39% | -0.51% | -62.63% | |
| 24 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.38% | — | — | |
| 25 | MSFT | Microsoft CORP | Stock-Tech | 1.38% | — | +156.79% | |
| 26 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.33% | -1.39% | EXIT | |
| 27 | ORA 2.5 07-15-27 SEPTBond | Ormat Technologies Inc | Bond | 1.32% | — | — | |
| 28 | PHVS | Pharvaris N.V. | Stock-Other | 1.28% | — | -19.26% | |
| 29 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.27% | -0.26% | -13.71% | |
| 30 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.24% | — | +95.86% | |
| 31 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.16% | — | +67.67% | |
| 32 | ABBV | Abbvie Inc | Stock-Healthcare | 1.10% | -0.05% | -16.53% | |
| 33 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.10% | -0.37% | -6.15% | |
| 34 | NVS | Novartis Ag-sponsored Adr | Stock-Healthcare | 1.05% | +0.12% | -26.00% | |
| 35 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.03% | +0.12% | — | |
| 36 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.03% | +0.55% | +0.25% | |
| 37 | ANNX | Annexon Inc | Stock-Other | 0.99% | — | — | |
| 38 | TLT | Ishares 20+ Year Treasury Bd | ETF-Gov Bonds | 0.97% | -0.12% | -81.58% | |
| 39 | IMVT | Immunovant Inc | Stock-Other | 0.96% | — | +31.91% | |
| 40 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.94% | +0.13% | +68.07% | |
| 41 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.90% | +0.05% | -18.46% | |
| 42 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.89% | +0.27% | — | |
| 43 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.84% | — | +18.87% | |
| 44 | ACOG | Alpha Cognition Inc | Stock-Other | 0.82% | +0.02% | -36.91% | |
| 45 | RZLT | Rezolute Inc | Stock-Other | 0.79% | — | -30.51% | |
| 46 | HELP | Cybin Inc | Stock-Other | 0.78% | +0.65% | -24.45% | |
| 47 | AMAT | Applied Materials Inc | Stock-Tech | 0.77% | +1.04% | NEW | |
| 48 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.75% | — | -26.86% | |
| 49 | ✓ | Immatics NV | Stock-Other | 0.74% | -0.14% | -36.70% | |
| 50 | SVRA | Savara Inc | Stock-Other | 0.70% | -0.03% | +2.03% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +3.9% | NEW | New buy |
| 2 | TSEM | Tower Semiconductor Ltd. | +2.2% | +330.10% | Add |
| 3 | BIIB | Biogen Inc | +1.7% | +263.88% | Add |
| 4 | FBRX | Forte Biosciences Inc | +1.5% | NEW | New buy |
| 5 | CDTX | Cidara Therapeutics Inc | +1.5% | +705.70% | Add |
| 6 | MLTX | Moonlake Immunotherapeutics | +1.4% | NEW | New buy |
| 7 | AM6 | Amicus Therapeutics Inc | +1.3% | NEW | New buy |
| 8 | NVDA | Nvidia CORP | +1.3% | +84.14% | Add |
| 9 | CYTK | Cytokinetics Inc | +1.2% | +125.38% | Add |
| 10 | NVMI | Nova Ltd. | +1.1% | -16.39% | Trim |
| 11 | TRVI | Trevi Therapeutics Inc | +1% | NEW | New buy |
| 12 | MSFT | Microsoft CORP | +1% | +156.79% | Add |
| 13 | ACAD | Acadia Pharmaceuticals Inc | +0.9% | NEW | New buy |
| 14 | TEVA | Teva Pharmaceutical-sp Adr | +0.8% | +3.10% | Add |
| 15 | ORIC | Oric Pharmaceuticals Inc | +0.6% | +68.07% | Add |
| 16 | ESLT | Elbit Systems Ltd. | +0.6% | NEW | New buy |
| 17 | PANW | Palo Alto Networks Inc | +0.6% | NEW | New buy |
| 18 | ✓ | Cyberark Software LTD. Cmn | +0.4% | NEW | New buy |
| 19 | TVTX | Travere Therapeutics Inc | +0.3% | +67.67% | Add |
| 20 | CAMT | Camtek Ltd. | +0.3% | +38.51% | Add |
| 21 | WIX | Wix.com Ltd. | +0.3% | +92.40% | Add |
| 22 | AMD | Advanced Micro Devices | +0.3% | NEW | New buy |
| 23 | KRYS | Krystal Biotech Inc | +0.2% | NEW | New buy |
| 24 | TSHA | Taysha Gene Therapies Inc | +0.2% | NEW | New buy |
| 25 | IBIT | Ishares Bitcoin Trust ETF | +0.2% | +163.25% | Add |
| 26 | ANNX | Annexon Inc | +0.2% | — | Unchanged |
| 27 | IMVT | Immunovant Inc | +0.2% | +31.91% | Add |
| 28 | AMAT | Applied Materials Inc | +0.2% | — | Unchanged |
| 29 | VSTM | Verastem Inc | +0.2% | NEW | New buy |
| 30 | UBER | Uber Technologies Inc | +0.2% | — | Unchanged |
| 31 | ORA | Ormat Technologies Inc | +0.2% | -7.14% | Trim |
| 32 | META | Meta Platforms Inc-class A | +0.2% | -14.41% | Trim |
| 33 | BCAX | Bicara Therapeutics Inc | +0.1% | NEW | New buy |
| 34 | GPCR | Structure Therapeutics Inc | +0.1% | +14.20% | Add |
| 35 | MRVL | Marvell Technology Inc | +0.1% | +24.29% | Add |
| 36 | MAZE | Maze Therapeutics Inc | +0.1% | +0.25% | Add |
| 37 | S | Sentinelone Inc -class A | +0.1% | NEW | New buy |
| 38 | ACOG | Alpha Cognition Inc | +0.1% | -36.91% | Trim |
| 39 | COGT | Cogent Biosciences Inc | +0.1% | +2.59% | Add |
| 40 | RNAGBP | Avidity Biosciences Inc | +0.1% | +18.87% | Add |
| 41 | ORA 2.5 07-15-27 SEPTBond | Ormat Technologies Inc | +0.1% | — | Unchanged |
| 42 | CGNT | Cognyte Software Ltd. | +0.1% | NEW | New buy |
| 43 | ELVN | Enliven Therapeutics Inc | +0.1% | +15.01% | Add |
| 44 | CATBUSD | Astria Therapeutics Inc | +0.1% | +35.62% | Add |
| 45 | RZLT | Rezolute Inc | +0.1% | -30.51% | Trim |
| 46 | AMZN | Amazon.com Inc | +0.1% | -11.38% | Trim |
| 47 | SLDB | Solid Biosciences Inc | +0.1% | NEW | New buy |
| 48 | PEPG | Pepgen Inc | 0% | NEW | New buy |
| 49 | CATX | Perspective Therapeutics Inc | 0% | -32.57% | Trim |
| 50 | CRVS | Corvus Pharmaceuticals Inc | 0% | -11.06% | Trim |
According to official SEC Form 13F filings, Sphera Funds Management LTD. reported a total U.S. public equity portfolio value of $766.5M across 104 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TEVA, NVMI, XBI) accounted for 11.8% of total reported equity market value during Q2 2025.
Top New Position Initiated
XBI
市值: $16.6M
Top Position Liquidated / Trimmed
NICE
前期市值: $5.1M
During Q2 2025, Sphera Funds Management LTD.'s top holdings by market value included TEVA (6.4%)、NVMI (4.9%)、XBI (3.9%). The largest single position, TEVA, represented 6.4% of total portfolio value.
In Q2 2025, Sphera Funds Management LTD. made 122 total portfolio adjustments, initiating 18 new buys, adding to 24 positions, trimming 53 holdings, and fully liquidating 27 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.